Skip to primary content
Skip to secondary content

Biotech 365

Main menu

  • Biotech 365
  • Companies
  • Healthcare Investors
    • Healthcare LPs
  • Healthcare Investors Matchmaking
  • Free DEMO
  • Services
    • Preclinical Studies Database
    • Scientific Due Diligence
    • CRO & CDMO Database
  • Contact

Tag Archives: Graham Mitchell

Antisense Therapeutics – antisense drugs

Posted on by

Antisense Therapeutics is a biopharma drug discovery and development company whose mission is to create, develop and commercialize novel antisense therapeutics.

Antisense Therapeutics – antisense drugs

Antisense Therapeutics Continue reading →

Posted in Biotech Companies, Biotech Companies Australia | Tagged ANP, anti-apoptotic, antisense, antisense drug, antisense drugs, antisense inhibitor, antisense technologies, antisense technology, antisense therapeutic, Antisense Therapeutics, Antisense Therapeutics - antisense drugs, Antisense Therapeutics Limited, antisense therapies, antisense therapy, ATL1101, ATL1102, ATL1103, blood vessel, cell death, central nervous system, Chris Belyea, CNS, cytotoxic drug, cytotoxic drugs, drug discovery, George Tachas, GHr, Graham Mitchell, growth hormone receptor, IGF-I, IGF-Ir, immune cell adhesion, insulin like growth factor 1 receptor, insulin-like growth factor-I, leukocyte, leukocytes, lymphocyte, lymphocytes, Mark Diamond, mouse model human prostate cancer, mouse model of human prostate cancer, multiple sclerosis, Phillip Hains, prostate cancer, Robert Moses, second generation antisense inhibitor, VLA-4, VLA4

        Services              Healthcare Investors Database              FAQs               CGU               Biotech & Pharma News             Contact
Proudly powered by WordPress